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Summary 
The properties of a new synthetic LDL binding material, consisting of fragments of loosely crosslinked 
hydrogel. based on sulfated polyvinylalcohol are described. When incubated with 20 times its volume of 
plasma, this material binds up to 95% of the LDL, even from plasma with severely elevated LDL 
cholesterol levels (up to 20 mM). In addition a cholesterol-rich subfraction of VLDL is bound but HDL is 
not bound. After about 10 min binder/plasma contact the LDL removal is complete and no other 
additives are required. LDL binding capacity is dependent on the average binder particle size. indicating a 
restricted penetration of LDL particles into the binder matrix. 
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Introduction 
Familial hypercholesterolemia (FH) is a geneti- 
tally inherited metabolic disorder, characterized 
by a severely increased level of plasma low density 
lipoproteins (LDL) (heterozygotes usually about 
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Ahhreuutrom: FH = familial hypercholesterolemia. HLP = 
hyperlipoproteinemia. LDL = low density lipoprotein. PBS = 
nhosnhate-buffered saline. and PVAS = sulfated oolwinvl- 
2-fold normal, homozygotes up to IO-fold normal). 
These increased plasma LDL levels are caused by 
a lack of specific cell surface LDL receptors. 
Elevated LDL levels present an increased risk of 
the occurrence of atherosclerosis. Homozygote pa- 
tients often die from a myocardial infarction be- 
fore age 20. Atherosclerotic disease affects 40% of 
heterozygote males and 20% of heterozygote 
females before the age of 40, being fatal for al- 
most a quarter of the males before they reach age 
50 [l]. 
A number of dietary and medical treatments 
reduce plasma LDL levels in FH patients to 
acceptable levels. especially when given in combi- 
nation [2]. However, some medicines are not effec- . . ._. 
alcohol tive in homozygotes and most have unpleasant 
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side-effects. An alternative method, used in pa- 
tients with persistent hypercholesterolemia, con- 
sists of extracorporeal blood treatment, performed 
either as plasma exchange [3] or by means of more 
selective techniques for LDL removal [4-61. The 
latter has been accomplished by perfusion of 
plasma or even full blood over columns or batches 
of immobilized heparin [4] or LDL antibodies [5], 
or by precipitation of LDL using buffered heparin 
161. 
In the present paper we report on the prepara- 
tion and properties of a new LDL binding material, 
based on sulfated polyvinylalcohol. This material 
may offer a suitable and more economic alterna- 
tive for the above-mentioned sepharose-based 
LDL sorbents. 
Materials and Methods 
Polyvinylalcohol (PVA) (MW 14000-86000, 
obtained from Janssen Chimica, Beerse, Belgium) 
was sulfated by reaction with a pyridineS0, 
complex in excess pyridine (obtained from Merck, 
Darmstadt, F.R.G.) (molar ratio pyridine- 
SO,/PVA = 1.3/l), for 90 min at 105OC (molar 
ratio pyridine/PVA = l/l). The pyridine-SO, 
complex was prepared by adding chlorosulfonic 
acid (obtained from Merck, Darmstadt, F.R.G.) 
dropwise to cooled pyridine (1 mole chloro- 
sulfonic acid/2 moles pyridine). After the sulfa- 
tion reaction the reaction mixture was diluted in 
distilled water and neutralized with NaOH; the 
pyridine was distilled off under vacuum and the 
sulfated PVA (PVAS) was purified by dialysis 
against distilled water. 
A dry product was obtained either by ethanol 
precipitation or by freeze-drying the dialyzed 
PVAS solution. A loosely cross-linked hydrogel 
was obtained by y-irradiation of aqueous solu- 
tions of PVAS in glass tubes of 8 mm diameter. 
Irradiation dose was varied between 25 and 100 
kGy (60Co, dose rate 3.5 kGy/h), PVAS con- 
centrations between 10 and 60% (w/w). 
After irradiation the hydrogels were pushed 
from the tubes and thoroughly washed with dis- 
tilled water. After this washing step (accompanied 
by extensive swelling; see Results) the PVAS hy- 
drogel was fragmented by one of the two follow- 
ing procedures: (1) freeze-drying of the gel fol- 
lowed by milling and sieving of the (dry) gel 
particles. By this method gel particles with a nar- 
row particle size distribution were obtained (sieve 
fractions: < 45 pm; 45-53 pm; 53-63 pm; 63390 
pm; 90-105 pm). (2) Equilibration of the hydrogel 
in PBS, followed by fragmentation in a Dounce 
homogenizer, yielded particle sizes between 50 
and 250 pm after reequilibration in PBS. Unless 
otherwise indicated the latter fragmentation 
method was used. 
Varying amounts of serum or of titrated or 
heparinized human plasma from healthy volun- 
teers or from different hyperlipoproteinemic pa- 
tients were incubated for 30 min with a constant 
volume of PVAS hydrogel particles, at 37OC in 
polystyrene tubes, which were mounted in a slowly 
rotating apparatus. Thereafter, the tubes were 
centrifuged for 10 min at 1000 x g to sediment the 
gel particles. 
The lipoprotein binding was studied either by: 
(1) determination of the total plasma cholesterol 
concentration before and after incubation or (2) 
isolation of the different lipoproteins (VLDL + 
IDL, LDL, HDL) by density gradient ultra 
centrifugation [7] before and after incubation of 
the whole plasma with the gel fragments, followed 
by determination of the lipoprotein concentrations 
by measuring the amount of cholesterol and tri- 
glyceride in each lipoprotein fraction. The frac- 
tions comprised VLDL + IDL (d= 1.006-1.019 
g/ml), LDL (d = 1.019-1.060 g/ml), HDL, (d = 
1.060-1.130 g/ml) and HDL, (d= 1.130-1.210 
g/ml). 
Cholesterol concentrations were determined 
according to [8]. Triglyceride concentrations were 
determined according to [9]. Binding was calcu- 
lated from the difference in concentration in the 
fluid phase before and after incubation with the 
absorbent. Mg2+ and Ca2+ concentrations were 
determined by standard atomic absorption tech- 
niques. Lp(a) and antithrombin-III (AT-III) con- 
centrations were determined by electro immunoas- 
say [lo] and apo B by radial immuno diffusion 
[II]. Albumin and CQ-, (Ye-, fi- and y-globulins 
concentrations were determined by electrophore- 
sis. Fibrinogen (Fb) and fibrin(ogen) degradation 
products (FDP/fdp) were quantitated by means 
of an enzyme-immunoassay, newly developed in 
collaboration with Organon Teknika. For Fb, 
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monoclonal antibody Y-18 was used as tagging 
[12] antibody and a non-specific monoclonal anti- 
body, recognizing fibrinogen in the D-domain, as 
catching antibody. For FDP/fdp, the monoclonal 
antibody FDP-14 [13] served as catching, and the 
non-specific anti-D monoclonal as tagging anti- 
body. All incubations were performed in dupli- 
cate, and were repeated unless the duplicate values 
differed less than 10%. 
Results 
Sulfution 
Depending on the molar ratio pyridine-SO, 
complex/PVA hydroxyl groups the substitution of 
the PVA hydroxyl groups by sulfate groups is 
60-95s. The experiments described were carried 
out with 80% sulfated PVA. 
Hydrogel formation 
After y-irradiation the binder contains 40-85s 
water. During the washing and equilibration in 
PBS the binder swells, due to osmotic pressure 
effects, to a water content of 95-99%. 
Table 1 shows the influence of both irradiation 
dose and PVAS concentration during radiation on 
the water content after equilibration in PBS. At 
higher water contents the hydrogels are more 
loosely cross-linked, improving the penetration of 
LDL particles into the binder matrix. A relatively 
low water content on the other hand indicates a 
high cross-linking density and therefore the possi- 
bility of a too finely meshed network inhibiting 
LDL penetration. 
Lipoprotein binding to PVAS-hydrogelparticles 
Upon incubation of PVAS-particles with 20 
TABLE 1 
PERCENTAGE CONTENT OF WATER AT SWELLING 
EQUILIBRIUM IN PBS OF PVAS HYDROGELS (DE- 
GREE OF SULFATION PVAS = 0.73) 
Irradiation dose 
(kGy) 
2x 
56 
90 
11X 
E PVAS during y-irradiation (w/w) 
10 15 20 
98.7 97.9 95.4 
9x.3 91.5 95.5 
98.3 96.2 95.2 
97.7 94.9 94.9 
O/L- 
0 
/ I 
1 5 lo 15 20 25 
Fig. 1. Influence of incubation time on cholesterol binding 
from pooled titrated plasma by fragments of cross-linked 
PVAS (5% by volume). Cholesterol concentration In this 
plasma: 4.3 mM; LDL cholesterol: 2.3 mM. 
times its volume of plasma (from a pool composed 
of plasma of 5 male, normolipidemic volunteers 
aged 25-37, not suffering from any metabolic 
endocrine or infectious disease), the particles re- 
moved about 60% of the total amount of 
cholesterol within 10 min (Fig. 1). This is 
equivalent to the total amount of cholesterol in 
the LDL fraction in that plasma. Table 2 shows 
lipoprotein profiles before and after incubation of 
1 volume binder particles with 20 volumes of 
titrated normal or hyperlipoproteinemic plasma. 
From these results it can be concluded that: (1) 
LDL is bound by 56-95%; (2) in case of HLP 
type IIa or b virtually all the LDL is bound; (3) 
VLDL is not, or for a much smaller percentage, 
bound in comparison to LDL. However, the per- 
cent cholesterol bound is always higher than the 
percent triglycerides bound from this fraction, in- 
dicating preferential binding of a cholesterol-rich 
subfraction of VLDL; (4) an extremely elevated 
VLDL concentration might reduce the LDL bind- 
ing capacity (type IV plasma); (5) HDLz and 
HDL, are not bound. In addition, the gel was 
found to bind Lp(a) antigen from whole serum 
containing a high level of this antigen with a 
similar efficiency as apo B (Table 3). 
Figure 2 shows the results of an experiment in 
which the LDL binder was incubated in varying 
binder/plasma ratios with 3 different plasmas 
with different total cholesterol levels and lipopro- 
tein spectra. The LDL binder has a very high 
capacity for LDL binding; even when the binder 
is incubated with lo-20 times its own volume of 
plasma containing an extremely elevated choles- 
FH 
fenotype 
Normal 
(male, 37) 
IIa 
(male, 49) 
IIa 
(male. 34) 
IIa 
(female, 64) 
IIb 
(female, 42) 
IV 
(male, 46) 
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terol level (20.7 mM) 70-80% of the total amount 
of cholesterol is removed, equivalent to 80-95% of 
LDL cholesterol (Fig. 2A). The absolute amount 
of bound cholesterol increases with increasing total 
plasma cholesterol concentration and with increas- 
ing amounts of plasma a maximum is reached at a 
TABLE 2 
LIPOPROTEIN PROFILES, BEFORE AND AFTER INCUBATION OF PVAS HYDROGEL PARTICLES WITH VARIOUS 
CITRATED PLASMAS, OBTAINED FROM FASTING SUBJECTS 
Plasma/binder ratio 20/l (v/v). 
VLDL 
Cholesterol 
Before 
(mmol/l) 
1.11 
After 
(mmol/l) 
0.41 
% bound 
(mmol/l) 
63 
Triglycerides 
Before After % bound 
(mmol/l) (mmol/l) (mmol/l) 
0.61 0.33 46 
LDL 
HDL, 
HDL, 
Rest 
Total 
VLDL 
IDL 
LDL 
HDLz 
HDL, 
Rest 
Total 
VLDL 
LDL 
HDL> 
HDL, 
Rest 
Total 
VLDL 
LDL 
HDLz 
HDL, 
Rest 
Total 
VLDL 
LDL 
HDL, 
HDL, 
Rest 
Total 
VLDL 
LDL 
HDLz 
HDL, 
Rest 
1.84 0.22 xx 0.18 0.04 78 
0.26 0.28 NS 0.05 0.06 NS 
0.60 0.64 NS 0.08 0.09 NS 
0.10 0.11 NS 0.01 0.01 NS 
3.91 1.66 5x 0.93 0.53 43 
1.X8 1.68 11 1.95 2.11 NS 
1.79 0.34 81 0.65 0.10 85 
3.47 0.97 72 0.59 0.20 66 
0.11 0.06 NS 0.06 0.04 NS 
0.35 0.33 NS 0.14 0.13 NS 
0.09 0.11 NS 0.04 0.05 NS 
7.69 3.49 55 3.43 2.62 23 
1.13 0.29 74 1.05 0.56 47 
6.19 0.31 95 0.45 0.01 9x 
0.07 0.09 NS 0.01 0.01 NS 
0.51 0.50 NS 0.02 0.05 NS 
0.12 0.10 NS 0.02 0.01 NS 
8.62 1.29 85 1.55 0.64 59 
1.41 0.30 79 0.37 0.22 41 
10.40 0.98 91 0.60 0.03 95 
0.50 0.47 NS 0.04 0.05 NS 
0.76 0.80 NS 0.06 0.07 NS 
0.11 0.11 NS 0.00 0.01 NS 
13.1x 2.66 80 1.07 0.38 64 
2.55 0.62 76 1.47 1.01 31 
6.90 0.37 95 0.56 0.10 82 
0.22 0.22 NS 0.05 0.05 NS 
0.58 0.59 NS 0.14 0.17 NS 
0.09 0.08 NS 0.03 0.01 NS 
10.34 1.88 x2 2.25 1.34 40 
11.49 8.77 24 10.41 7.86 24 
2.36 1.03 56 0.38 0.22 42 
0.26 0.24 NS 0.06 0.07 NS 
0.76 0.81 NS 0.13 0.15 NS 
0.09 0.09 NS 0.01 0.01 NS 
Total 14.96 24 
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Fig. 2. Cholesterol binding by fragments of cross-linked PVAS 
as a function of the plasma/binder ratio (v/v), using normal 
or type II hyperlipoproteinic defined titrated plasmas. 
-1: Binding as percent of total amount of cholesterol brought 
in the incubation. B: Amount of cholesterol bound to the gel 
fragments. Total cholesterol concentrations in these plasmas: 
A: 4.3 mM (pool: 1.39 mM TG); a: 11.2 mM (male: 2.3 ml 
TG); w: 20.7 mM (male: 3.25 mM TG). 
plasma/binder ratio of 20/l-40/1 (by volume). 
At higher ratios the absolute binding decreases 
(Fig. 2B). 
As shown in Table 1 a higher concentration of 
PVAS during irradiation results in a more densely 
cross-linked network. In order to study the effect 
TABLE 3 
BINDING OF APO B AND Lp(a) BY A PVAS HYDROGEL 
(DS = 0.73: 15% PVAS DURING y-IRRADIATION) FROM 
5 DIFFERENT SERA 
Incubation of 1 ml serum with 80 ~1 PVAS gel suspension. 
Apo B cont. 06 removed ’ Lp(a) cow. % removed (SD) ’ 
beforc inc before inc. 
(mg/dl) (mg/dl) 
160.1 76.2 
137.2 70.9 
145.6 76.4 
145.6 73.1 
131.1 66.1 
* 1 cxpenment. 
h 3 experiments. 
x3.4 75.1 (6.7) 
143.x 40.2 (4.4) 
Y3.7 61.1 (3.X) 
111.0 74.2 (7.0) 
x9.7 64.9 (5.0) 
Fig. 3. Influence of concentration of PVAS (LMW, DS = 0.8X) 
during y-irradiation, on binding of cholesterol from titrated 
plasma (from a local bloodbank total cholesterol 5.6 mM) by 
the resulting cross-linked, swollen and fragmentated material. 
Plasma/binder ratios: 20/l (0 ---0). 40/l (O-- 0). 
60/l (A- A). 
of the mesh size of the gel on the LDL binding we 
prepared a series of hydrogels with increasing 
concentrations PVAS during y-irradiation (thus 
increasing cross-linking density). The results are 
summarized in Fig. 3. In this figure we can dis- 
tinguish 3 different regions: (1) below 30% PVAS 
no hydrogel is formed, (2) between 30 and 40% 
PVAS the cholesterol binding is independent of 
60 
L------ -. 
‘\ 
40- : 
‘\ -h : : b ‘. 
\ 
‘-.* 
201 ‘\_ 
Oi--Tr-- 80 
Fig. 4. Influence of binder particle size on cholesterol binding 
(titrated plasma from a local bloodbank); total cholesterol 4.8 
mM. Cross-linked PVAS was prepared by y-irradiation of a 
25% (w/w) solution of PVAS (LMW, DS = 0.88). The result- 
ing material was dialyzed against water, lyophilized milled and 
sieved as described in Material and Methods. Particle size (dry, 
according to the mesh of the sieves): v < 45 pm. A 45-53 pm. 
??53-63 pm, 0 63-90 nm, v 90-105 pm, 0 Dounce (wet 
disruption). 
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Fig. 5. Binding of antithrombin-III in titrated plasma (from 
the regional bloodbank in Enschede) by fragments of cross-lin- 
ked PVAS. The binding is expressed as % of the initial amount 
of AT-III in the plasma, and plotted as a function of the 
plasma/binder ratio (v/v). 
the gel network mesh size, (3) at PVAS concentra- 
tions higher than 40% the mesh size of the gel 
becomes limiting for effective LDL penetration, 
thus leading to a reduced cholesterol binding. 
In order to study the effect of the gel particle 
size on the cholesterol binding, gel particles were 
prepared by milling and sieving a freeze-dried 
hydrogel. As shown in Fig. 4 the cholesterol bind- 
ing increases with decreasing gel particle size (thus 
increasing gel surface). With each sieve-fraction, 
except the coarsest, the amount of LDL cholesterol 
bound reached a maximum upon addition of in- 
creasing amounts of plasma and decreased again 
TABLE 4 
REMOVAL OF FIBRINOGEN (Fb) AND GENERATION 
OF FIBRINOGEN DEGRADATION PRODUCTS (FPD/ 
fdp) IN CITRATED PLASMA OBTAINED FROM A LO- 
CAL BLOODBANK BY CROSS-LINKED PVAS FRAG- 
MENTS 
Mean and SD, n = 3. 
Plasma/ Fb removed FDP/fdp 
binder 
ratio 
(v/v) 
20/l 
40/l 
60/l 
(mg/ml binder) (S of initial Fb) formed 
(ng/ml 
28.3_+2.1 
50.7 * 2.x 
5X.8 + 7.3 
95.9_+ 2.5 
88.Oi 6.4 
68.1* 10.3 
binder) 
15.1k2.8 
18.5 _c 5.7 
19.25 5.2 
at higher amounts of plasma. The height of the 
maximum increased with decreasing average par- 
ticle size. 
The binding of other plasma components was 
also investigated. At a titrated plasma/ binder 
ratio of 20/l, 13% of the total calcium and 22% of 
the total magnesium was bound. At plasma/ 
binder ratios of 40/l and higher, divalent cation 
binding dropped to undetectable values. The bi- 
nding of AT-III appeared to be strongly depen- 
dent on the plasma/binder ratio. Up to a 
plasma/binder ratio of 2, virtually all the AT-III 
is bound. An increase of this ratio results in a 
rapid reduction of the AT-III binding, so that at 
plasma/binder ratios over 20/l, less than 10% of 
the AT-III is bound by the PVAS hydrogel (Fig. 
5). Albumin and CX,-, q-, p- and y-globulins were 
not appreciably bound to the gel fragments in 
incubations with plasma/binder ratios of 20/l or 
higher (not shown). Fibrinogen, however, was 
largely removed from titrated plasma in such in- 
cubations, which could be ascribed to extensive 
Fb degradation (Table 4). 
Discussion 
Loosely cross-linked, highly sulfated PVA hy- 
drogels are able to bind LDL selectively and with 
high capacity from blood plasma. The LDL bind- 
ing is reduced by very high VLDL levels (type IV 
HLP) and at very high plasma/binder ratios by 
other plasma factors *. 
The LDL binding also depends on the mesh 
size of the network (a too finely meshed network 
inhibits LDL penetration into the gelmatrix) and 
on the particle size of the binder i.e. the total 
binder surface. The effects of both gel surface and 
degree of cross-linking on LDL binding indicate a 
restricted penetration of the LDL particle into the 
gelmatrix. Theoretical calculations for LDL pene- 
tration into the gelmatrix predict a penetration 
depth of LDL in the matrix of 10 pm. This means 
that only part of the total gel volume of the 
particles used is actually involved in the LDL 
* In separate experiments binding of isolated LDL was found 
to be inhibited by addition of the dialyzed d > 1.21 g/ml 
uhracentrifugation fraction of serum or titrated plasma 
(H.J.M. Kempen, unpublished observation). 
binding process. Therefore the LDL binding 
capacity could theoretically be increased by fur- 
ther reducing the gel particle size, but this will 
probably introduce problems in filtering the gel 
from the treated plasma. 
In addition to LDL, these gels bind a cholesterol 
rich subfraction from the d < 1.019 g/ml lipopro- 
teins. A similar cholesterol-rich VLDL subfraction 
was isolated from the total d < 1.006 g/ml lipo- 
proteins by passage through a column of hepa- 
rinsepharose [14]. Removal of these particles can 
be considered as favourable, since these particles 
are thought to be atherogenic [15]. Furthermore 
Lp(a), also considered as an atherogenic particle 
[16], is bound to a considerable extent, whereas 
HDLz and HDL, are virtually not adsorbed. Bin- 
ding of other plasma proteins was also investi- 
gated. Binding of AT-III, albumin and various 
globulins was less than 10% at plasma/binder 
ratios above 20/l. Fibrinogen was largely re- 
moved, however mostly by degradation. This loss 
of fibrinogen is caused by extensive activation of 
Factor XII and prekallikrein by the cross-linked 
PVAS fragments (G. Dooijewaard and C. Kluft, 
unpublished), thus initiating both clotting and 
fibrinolysis cascades in the titrated plasma. 
Compared to other LDL binders, such as im- 
mobilized heparin or dextran sulfate, this binder 
has a very high capacity for LDL binding. As 
shown in Fig. 2 the binder removes almost all the 
LDL from 10 to 20 times its own volume of 
plasma, even when plasma with extremely elevated 
LDL levels is used. Therefore, LDL plasma levels 
in FH patients could theoretically be lowered by 
90% with only 150-300 ml binder particles. In a 
clinical situation, however, the LDL reduction will 
be less pronounced due to the limitations in ex- 
tracorporeal blood volume (about 500 ml) and 
also due to the dilution of untreated with treated 
blood, resulting in a logarithmic decrease of the 
LDL level. 
In contrast to immobilized heparin and dextran 
sulfate, no additives such as divalent cations are 
required for LDL removal by cross-linked PVAS 
particles, which not only simplifies clinical proce- 
dures, but also permits the use of citrate-based 
anticoagulants. 
The results of these experiments suggest that an 
extracorporeal plasma treatment with sulfated 
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polyvinylalcohol gels could offer a new and useful 
technique for lowering LDL levels of FH patients. 
Further research will be focussed on the biocom- 
patibility of this new LDL binding material, as 
well as on the manner in which it can be incorpo- 
rated in a device for extracorporeal LDL aphere- 
sis. 
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